Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients with Borderline Resectable Pancreatic Cancer - The A021501 Trial - Reply

Matthew H.G. Katz; Joseph M. Herman; Eileen M. O'Reilly

doi:10.1001/jamaoncol.2022.6147

Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients with Borderline Resectable Pancreatic Cancer - The A021501 Trial - Reply

Matthew H.G. Katz, Joseph M. Herman, Eileen M. O'Reilly

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	277-278
Number of pages	2
Journal	JAMA Oncology
Volume	9
Issue number	2
DOIs	https://doi.org/10.1001/jamaoncol.2022.6147
State	Published - Feb 16 2023
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1001/jamaoncol.2022.6147

Cite this

@article{278d995a4ac440a4b0fa1f02923f3b7b,

title = "Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients with Borderline Resectable Pancreatic Cancer - The A021501 Trial - Reply",

author = "Katz, {Matthew H.G.} and Herman, {Joseph M.} and O'Reilly, {Eileen M.}",

note = "Funding Information: Conflict of Interest Disclosures: Dr Herman reported receiving personal fees (consulting) from Boston Scientific and HistoSonics; in addition, Dr Herman had a patent for Oncospace issued; and Northwell Health receives funding from the 1440 Foundation for salary support to lead the Canopy Cancer Collective. No other disclosures were reported. ",

year = "2023",

month = feb,

day = "16",

doi = "10.1001/jamaoncol.2022.6147",

language = "English (US)",

volume = "9",

pages = "277--278",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "2",

}

TY - JOUR

T1 - Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients with Borderline Resectable Pancreatic Cancer - The A021501 Trial - Reply

AU - Katz, Matthew H.G.

AU - Herman, Joseph M.

AU - O'Reilly, Eileen M.

N1 - Funding Information: Conflict of Interest Disclosures: Dr Herman reported receiving personal fees (consulting) from Boston Scientific and HistoSonics; in addition, Dr Herman had a patent for Oncospace issued; and Northwell Health receives funding from the 1440 Foundation for salary support to lead the Canopy Cancer Collective. No other disclosures were reported.

PY - 2023/2/16

Y1 - 2023/2/16

UR - http://www.scopus.com/inward/record.url?scp=85148306849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85148306849&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2022.6147

DO - 10.1001/jamaoncol.2022.6147

M3 - Letter

C2 - 36454565

AN - SCOPUS:85148306849

SN - 2374-2437

VL - 9

SP - 277

EP - 278

JO - JAMA Oncology

JF - JAMA Oncology

IS - 2

ER -

Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients with Borderline Resectable Pancreatic Cancer - The A021501 Trial - Reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this